These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30552308)
1. Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management. Harsch IA; Kaestner RH; Konturek PC J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552308 [TBL] [Abstract][Full Text] [Related]
2. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea. Omori K; Nomoto H; Nakamura A; Takase T; Cho KY; Ono K; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H J Diabetes Investig; 2019 Mar; 10(2):367-374. PubMed ID: 29963781 [TBL] [Abstract][Full Text] [Related]
3. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Khamaisi M; Leitersdorf E Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665 [TBL] [Abstract][Full Text] [Related]
4. Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus. Mennecart M; Mondon K; Malherbe C; Constans T J Am Geriatr Soc; 2014 Dec; 62(12):2460-2. PubMed ID: 25516054 [No Abstract] [Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
6. Hypoglycemia probably due to accidental intake of repaglinide. Lee IT; Sheu WH; Lin SY Chang Gung Med J; 2002 Nov; 25(11):783-6. PubMed ID: 12553369 [TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience. Fisher SJ; Huang X; Pawaskar M; Witt EA; Rajpathak S; Shankar RR; Inzucchi SE Endocrine; 2018 Jun; 60(3):435-444. PubMed ID: 29460218 [TBL] [Abstract][Full Text] [Related]
8. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Johansen OE; Birkeland KI Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Hee Nam Y; Brensinger CM; Bilker WB; Flory JH; Leonard CE; Hennessy S Clin Pharmacol Ther; 2022 Jan; 111(1):218-226. PubMed ID: 34312836 [TBL] [Abstract][Full Text] [Related]
10. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475 [TBL] [Abstract][Full Text] [Related]
11. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Lund A; Knop FK Curr Med Res Opin; 2012 May; 28(5):731-6. PubMed ID: 22462528 [TBL] [Abstract][Full Text] [Related]
12. Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk? Schloot NC; Haupt A; Schütt M; Badenhoop K; Laimer M; Nicolay C; Reaney M; Fink K; Holl RW Diabetes Metab Res Rev; 2016 Mar; 32(3):316-24. PubMed ID: 26409039 [TBL] [Abstract][Full Text] [Related]
13. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany. Göke R; Gruenberger JB; Bader G; Dworak M Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429 [TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122 [TBL] [Abstract][Full Text] [Related]
15. Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. Han X; Chiang C; Leonard CE; Bilker WB; Brensinger CM; Li L; Hennessy S Epidemiology; 2017 May; 28(3):459-468. PubMed ID: 28169935 [TBL] [Abstract][Full Text] [Related]
16. Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review. Khamaisi M Diabet Med; 2012 Sep; 29(9):1214-5. PubMed ID: 22414218 [No Abstract] [Full Text] [Related]
17. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes. Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K; J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524 [TBL] [Abstract][Full Text] [Related]
18. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113 [TBL] [Abstract][Full Text] [Related]
19. Repaglinide induced acute hepototoxicity. Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361 [TBL] [Abstract][Full Text] [Related]
20. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study. Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]